COVID-19: New masking policy, vaccinations, testing and general information. Learn more

Faculty Publications

MetroHealth’s gastroenterology team is dedicated to research, sharing remarkable discoveries with the world. These are just some of the results our team has published in medical journals between 2014 and 2016.

  1. Fass R, Maradey-Roniero C. Commentary: the proton pump inhibitor test - does it have a role in eosinophilic oesophagitis? Aliment Pharmacol Ther. 2014;39(8):896-7.
  2. Maradey-Romero C, Kale H, Fass R. Nonmedical therapeutic strategies for nonerosive reflux disease. Clin gastroenterol. 2014;48(7):584-9.
  3. Maradey-Romero C, Fass R. New therapies for non-cardiac chest pain. Curr Gastroenterol Rep. 2014;16(6):390.
  4. Fass R. Functional heartburn. Gastroenterol Hepatol (NY). 2014;10(6):381-3.
  5. Sheikh I, Waghray A, Waghray N, Dong C, Wolfe MM. Consumer use of over-the¬ counter proton pump inhibitors in patients with gastroesophageal reflux disease. Am J Gastroenterol. 2014;109(6):789-94.
  6. Waghray N, Waghray A, Mullen K. Treatment options for covert hepatic encephalopathy. Curr treat op gastroenterol. 2014;12(2):229-41.
  7. Ciociola AA, Cohen LB, Kulkarni P. How drugs are developed and approved by the FDA: current process and future directions. Am J Gastroenterol. 2014;109(5):620-3.
  8. Dickman R, Maradey-Romero C, Fass R. The role of pain modulators in esophageal disorders - no pain no gain. Neurogastroenterol Motil. 2014;26(5):603-10.
  9. Wolfe MM, Boylan MO. Obesity and the Gastrointestinal Tract: You Are What You Eat. J clin gastroenterol. 2014.
  10. Lopez-Alvarenga JC, Orr W, Vargas-Romero JA, Remes-Troche JM, Morales-Arambula M, Soto-Perez JC, et al. Relief of Night-time Symptoms Associated With Gastroesophageal Reflux Disease Following 4 Weeks of Treatment With Pantoprazole Magnesium: The Mexican Gastroesophageal Reflux Disease Working Group. J Neurogastroenterol Motil. 2014;20(1):64-73.
  11. Maradey-Romero C, Fass R. New and future drug development for gastroesophageal reflux disease. J Neurogastroenterol Motil. 2014;20(1):6-16.
  12. Gingold-Belfer R, Peled N, Levy S, Katz N, Niv Y, Fass R, et al. Impaired sleep quality in Crohn's disease depends on disease activity. Dig Dis Sci. 2014;59(1):146-51.
  13. Maradey-Romero C, Gabbard S, Fass R. Treatment of esophageal motility disorders based on the chicago classification. Cur treat in gastroenterol. 2014;12(4):441-55.
  14. Pelchat ML BB, Cuomo R, DiSalle F, Fass R, Wise P. Carbonation: A reiew of sensory mechanisms and health effects. Nutrition Today 2014;49:308-12. 2014.
  15. Waghray N, Veluru CS, Maxwell J. Acute hepatitis in pregnancy. Gastroenterology. 2014;147(1):e12-3.
  16. Waghray A, Waghray N, Kanna S, Mullen K. Optimal treatment of hepatic encephalopathy. Minerva gastroenterologica e dietologica. 2014;60(1):55-70.
  17. Abdallah J, Hassan T, Kyprianou A. When it comes to gastric cancer, there is more to it than H. pylori! Am J Gastroenterol. 2014;109(7):1080-1.
  18. Abdallah J, Hassan T, Kyprianou A. Re: proton pump inhibitors and risk for recurrent Clostridium difficile infection among inpatients. Am J Gastroenterol. 2014;109(4):601-2.
  19. Hassan T, Periyalwar P, Tahir S, Kyprianou A. Low-residue diet with bowel prep: not for everyone! Am J Gastroenterol. 2014;109(4):599.
  20. Sengodan P, Anna K, Reed S, Shah B, Jain A, Kyprianou A. A case of recurrent bleeding stomal varix controlled using embolization with a liquid copolymer: an effective therapy for palliation. Journal of palliative medicine. 2014;17(1):85-7.
  21. Nasrollah L, Maradey-Romero C, Jha LK, Gadam R, Quan SF, Fass R. Naps are associated more commonly with gastroesophageal reflux, compared with nocturnal sleep. Clin gastroenterol hepatol: 2015;13(1):94-9.
  22. Abdallah J, Maradey-Romero C, Lewis S, Perzynski A, Fass R. The relationship between length of Barrett's oesophagus mucosa and body mass index. Aliment Pharmacol Ther. 2015;41(1):137-44.
  23. Atluri DK, Chandar AK, Fass R, Falck-Ytter Y. Systematic review with meta-analysis: selective serotonin reuptake inhibitors for noncardiac chest pain. Aliment Pharmacol Ther. 2015;41(2):167-76.
  24. Maradey-Romero C, Fass R. Antidepressants for Functional Esophageal Disorders: Evidence- or Eminence-Based Medicine? Clin gastroenterol and hepatol. 2015;13:260- 62.
  25. Fass R. Esophageal mucosa! impedance: is it time to forgo prolonged gastroesophageal reflux recordings? Gastroenterology. 2015;148(2):282-5.
  26. Hussain ZH, Henderson EE, Maradey-Romerao C, George N, Fass R, Lacy BE. The Proton Pump Inhibitor Non-Responder: A Clinical Conundrum. Clin Transl Gastroenterol. 2015;6:e115.
  27. Maradey-Romero C, Fass R. Letter: oesophageal eosinophilia must be excluded before determining prevalence of eosinophilic oesophagitis--authors' reply. Aliment Pharmacol Ther. 2015;42(5):629
  28. Dickman R, Maradey-Romero C, Gingold-Belfer R, Fass R. Unmet Needs in the Treatment of Gastroesophageal Reflux Disease. J Neurogasteroenterol Motil 2015;21(3):209-19.
  29. Eisig JN, Navarro-Rodriguez T, Teixeira AC, Silva FM, Mattar R, Chinzon D, Haro C, Diniz MA, Moraes-Filho JP, Fass R, Barbuti RC. Standard Triple Therapy versus Sequential Therapy in Helicobacter phlori Eradication : A Double-Blind, Randomized, and Controlled Trial. Gastro Res Pract 2015;2015:818043
  30. Maradey-Romero C, Prakash R, Lewis S, Perzynski A, Fass R. The 2011-2014 prevalence of eosinophilic oesophagitis in the elderly amongst 10 million patients in the United States. Aliment Pharmacol Ther 2015;41:1016-22
  31. Abdallah J, Lewis S, Fass R. Letter: is there a relationshop between Barrett's oesophagus length and body mass index? Authors' reply. Aliment Pharmacol Ther 2015;41(7):702-3
  32. Jha LK, Maradey-Romero C, Gadam R, Herschcovici T, Fass OZ, Quan SF, Guillen J, Fass R. The effect of antireflux treatment on the frequency of awakenings from sleep in patients with Gastroesophageal reflux disease. 2015;27(2):237-45
  33. Boylan MO, Glazebrook PA, Tatalovic M, Wolfe MM. Gastric inhibitory polypeptide immunoneutralization attenuates development of obesity in mice. Am J Physiol Endocrinol Metab. 2015;309(12):E1008-18
  34. Syed A, Kyprianou A. Unsedated Transnasal Endoscopy (uTNE): Not Quite Ready to Replace Sedated Esophagogastroduodenoscopy (sEGD). Am J Gastroenterol 2015;110(6):936-7
  35. Syed A, Haassan T, Kyprianou A. Many factors affecting the quality of bowel preparation need to be discussed when comparing different regimes. Am J Gastroenterol 2015;110(3):473-4
  36. Khallafi H, Qureshi K. Imaging Based Methods of Liver Fibrosis Assessment in Viral Hepatitis: A Practical Aproach. lnterdiscip Perspect Infect Dis 2015;2015:809289
  37. Waghray A, Waghray N, Mullen K. Management of covert hepatic encephalopathy. J Clin Exp Hepatol 2015;5(Suppll):S75-81
  38. Aziz Q, Fass R, Gyawali CP, Miwa H, Pandolfino JE, et al. Functional Esophageal disorders. Gastroenterology 2016;150:1368-1379
  39. Khan F, Maradey-Romero C, Ganocy S, Frazier R, Fass R. Utilisation of surgical dundoplication for patinets with gastro-oesophageal reflux disease in the USA has declined rapidly between 2009 and 2013. Aliment Phar; 2016;43(11):1124-31.
  40. Abdallah J, Fass R. Progression of Jackhammer Esophagus to Achalasia: Author's Reply. J Neurogastroenterol Motil. 2016;30:22(2)350
  41. Pantham G, Ganesan S, Einstadter D, Jin G, Weinberg A, Fass R Assessment of the incidence of squamous cell papilloma of the esophagus and the presence of high-risk human papilloma virus. Dis Esophagus. 2016
  42. Heading RC, Thomas EC, Sandy P, Smith G, Fass R, Hungin PS. Discrepancies between upper GI symptoms described by those who have them and their identification by conventional medical terminology: a survey of sufferers in four countries. J Gastro Enterol 2016;28(4):455-62
  43. Abdallah J, Fass R. Progression of Jackhammer Esophagus to Type II Achalasia. J Neurogastroenterol Motil. 2016 31;22:153-6
  44. George N, Abdallah J, Maradey-Romero C, Gerson L, Fass R. Review article: the current treatment of non-cardiac chest pain. Aliment Pharmacol Ther 2016;43:213-39
  45. Gabbard SL, Fass R, Maradey-Romero C, Gingold Belfer R, Dickman R. Identifying Minimal Changes in Nonerosive Reflux Disease: Is the Pay Worth the Labor? J Clin Gastroenterol 2016;50(1):11-6.
  46. Jha LK, Fass R, Gadam R, Maradey-Romero C, Nasrollah L, Hershcovici T, Quan SF, Dickman R,, The Effect of Ramelteon on Heartburn Sypmtoms of Patients with Gastroesophageal Reflux Disease and Chronic Insomnia: A Pilot Study. J Clin Gastroenterol 2016;50(2):e19-24.
  47. Tan VP, Wong BC, Wong WM, Leung WK, Tong D, Yuen MF, Fass R. Gastroesophageal Reflux Disease: Cross-Sectional Study Demonstrating Rising Prevalence in a Chinese Population. J Clin Gastroenterol 2016;50(1):el-7
  48. Waghray A, Michel-Calderon A, Kyprianou A, Waghray N. Severe hemorrhagic gastritis after percutaneous endoscopic gastrostomy tube placement. Ann Gastroenterol 2016;29(2):226
  49. Hassan T, Khan F, Kyprianou A. A Not So Benign Abdomen! Gastroenterol 2016;150(2):el-2
  50. Waghray A, Waghray N, Khallafi H, Menon KV. Vaccinating Adult Patients with Cirrhosis: Trends over a Decade in the United States. Gastroenterol Res Pract. 2016;2016:5795712
  51. Lee TH, Rangan V, Khallafi H. A Case of Sphenoid Sinus Metastasis in Hepatocellular Carcinoma. Hepatology 2016;63(6):2050-3
  52. Waghray A, Jain A, Waghray N. Colorectal cancer screening in African Americans: practice patterns in the United States. Are we doing enough?Gastroenterol Rep 2016;4(2):136-40
  53. Waghray A, George N, Waghray N. Gastrointestinal pseudomelanosis. Ann Gastroenterol 2016;29(1):92
  54. Sandhu D, Fass R. The Role of Chemoprevention in Barrett's esophagus. Gastroenterol and Esdoscop News, 2016:11-16
  55. Rodriguez-Torres M, Lawitz E, Yangco B, Jefffers L, Han SH, Thuluvath PJ, Rustgi V, Harrison S, Ghalib R, Vierling JM, Luketic V, Zamor PJ, Ravendhran N, Morgan TR, Pearlman B, O'Brien C, Khallafi H, Pyrsopoulos N, Kong G, McPhee F, Yin PD, Hughes E, Treitel M. Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection. Ann Hepatol 2016; 15(6):834-845
  56. Khan F, Maradey-Romero C, Ganocy S, Frazier R, Fass R. Utilisation of surgical fundoplication for patients with gastro-oesophageal reflux disease in the USA has declined rapidly between 2009 and 2013. Aliment Pharmacol Ther 2016, 43(11):1124-31
  57. Aziz Q, Fass R, Gyawali P, Miwa H, Pardolfino JE, et al.  Functional Esophageal disorders. Gastroenterology 2016;150:1368-1379
  58. Frazier RD, Fass R. Editorial: management of eosinophilic oesophagitis - efficacy vs effectiveness. Aliment Pharmacol Ther 2016;44(2):198-9
  59. Fass R, Frazier R. The role of Dexlansoprazole in the management of GERD. Ther Ad Gastroenterol 2017;10:243-51
  60. Sandhu DS, Fass R. Current trends in the management of GERD Gut & Liver 2018;12:7-16
  61. Fass R, Cahn F, Scotti DJ, Gregory DA. Systematic review and meta-analysis of controlled and prospective cohort efficacy studies of endoscopic radiofrequency for treatment of GERD. Surg Endosc 2017; 31:4865-82
  62. Syed A, Frazier R, Maradey-Romero C, Fass R. The relationship between eosinophilic esophagitis and esophageal cancer. Dis Esoph 2017; 30:1-5 (editor’s choice)
  63. Yamasaki T, Fass R. Non cardiac chest pain (NCCP): Diagnosis and management. Curr opin Gastroenterol 2017; 33:293-300
  64. Niv Y, Ho SB, Fass R, Rokkas T. Mucin expression in the esophageal malignant and premalignant states - A systematic review and meta- analysis. J Clin Gastroenterol 2018; 52:91-96
  65. Calles-Escandon J, Koch KL, Hasler WL, Van Natta ML, Herman WH etal.  Safety and efficacy of Sensor-augmented continuous subcutaneous insulin infusion in patients with diabetic Gastroparesis, PLOS ONE 2018;13:e0194759.
  66. George NS, Rangan V, Geng Z, Khan F, Frazier R, Kichler A, Gabbard S, Ganocy S, Fass R.  Distribution of esophageal motor disorders in diabetic patients with dysphagia. J Clin Gastroenterol 2017; 51:890-895
  67. Gyawali CP, Fass R. Current and new treatments for gastroesophageal reflux disease. Gastroenterolgy 2018; 154:302-318
  68. Yamasaki T, Fass R. Reflux Hypersensitivity – A new functional esophageal disorder J Neurogastroenterol Motil 2018; 23:495-503 
  69. Rangan V, George NS, Khan F, Geng Z, Kichler A, Gabbard S, Gittlem H, Fass R. Severity of ineffective esophageal motility (IEM) is associated with utization of skeletal muscle relaxants. Neurogastroenterol Mitil 2018;30:e13235.
  70. Yamasaki T, Fass R. Functional heartburn – An update. Gastroenterol Hepatol 2017; 12:725-34
  71. Akinsiku O, Yamasaki T, Brunner S, Ganocy S, Fass R. High resolution versus conventional esophageal manometry in the assessment of esophageal motor disorders in patients with noncardiac chest pain. Neurogastroenterol Motil 2018; 30:e13282
  72. Laique S, Singh T, Dornblaser D, Gadre A, Rangan V, Fass R, Kirby D, Chatterjee S, Gabbard S. Patient characteristics and associated systematic diseases in patients with esophageal absent contractility. J clin Gastroenterol 2017 (in press)
  73. Domingues G, Prado J, Fass R. Refractory Heartburn – A challenging problem in clinical practice. Dig Dis Sci 2018; 63:577-82
  74. Yadlapati R, Vaezi MF, Vela M, Spechler SJ, Shaheen N, Richter J, Lacy BE Katzka D, Datz PO, Kahrilas P, Gyawali CP, Gerson L, Fass R, Castell DO, Craft J, Hillman L, Pandolfino JE. Management options for patients with proven GERD and persistent symptoms on proton pump inhibitors: Recommendations from an expert panel. AM J Gastroenterol 2018; 113:980-86
  75. Yamasaki T, Fass R. Reflux hypersensitivity – What’s in the name? Neurogastro LATAM Rev. 2018; 2:1-13
  76. Abdallah J, George N, Yamasaki T, Ganocy S, Fass R. Most patients with gastroesophageal reflux disease who failed proton pump inhibitor therapy also have functional esophageal disorders. Clin Gastroenteal Hepatol 2018 (in press)
  77. Tawil J, Fass R. Globus: current concepts and dilemmas. J Clin Gastroenterol 2018;52:845-52
  78. Yamasaki T, Hemmond C, Eisa M, Ganocy S, Fass R. The changing epidemiology of GERD - Are patients getting younger? Journal Neurogastroenterol Motil 2018; 24:559-569
  79. Sandhu D, Fass R. Stress and Gastroesophageal reflux disease. Med Sci 2018 (in press)
  80. Fass R. Accepting the torch. J Clin Gastroenterol 2017;5:1
  81. Fass R. An overview of transoral incisionless fundoplication and magnetic sphincter augmentation for GERD. Gastroenterol Hepatol 2017;13:50-52.
  82. Fass R, Rass SS. Psychological comorbidity and chronic heartburn – which is the chicken, and which is the egg? Dig Dis Sci 2017; 62:823-25.
  83. Fass OZ, Fass R. Overlap between GERD and functional esophageal disorders – a pivotal mechanism for treatment failure. Cur treat opt Gastroenterol 2018 (in press)
  84. Waghray A, Waghray N, Perzynski AT, Votruba M, Wolfe MM. Optimal Omeprazole Dosing and Symptom Control: A Randomized Controlled Trial (OSCAR Trial). Dig Dis Sci. 2018 Aug 9.doi:10.1007/d10620-018-5235-9 [Epub ahead of print]
  85. Waghray A. Waghray N, Khallafi H, Menon KV. Vaccinating Adult Patients with Cirrhosis: Trends over a Decade in the United States. Gastroenterol Res Pract. 2016;2016:5795712. Doi: 10.1155/2016/5795712/ Epub 2016 April 30
  86. Waghray A, Jain A, Waghray N. Colorectal cancer screening in African Americans” practice patterns in the United States. Are we doing enough? Gastroenterol Rep (Oxf). 2016 May;4(2):136-40. Doi:10.1093/gastro/gow005.Epub 2016 Apr 11.
  87. Waghray A, Michel-Calderon A, Kyprianou A, Waghray N. Severe hemorrhagic gastritis after percutaneous endoscopic gastrostomy tube placement. Ann Gastroenterol. 2016 Apr-Jun; 29(2):226. Doi: 10.20524/aog.2016.00174.
  88. Rodriguez-Torrez M, Lawitz E, Yangco B, Jeffers L, Han SH, Thuluvath PJ, Rustgi V, Harrison S, Ghalib R, Vierling JM, Luketic V, Zamor PJ, Ravendhran N, Morgan TR, Pearlman B, O’Brien C, Khallafi H, Pyrsopoulos N, Kong G, McPhee F, Yin PD, Hughes E, Treitel M. Daclatasvir and Peginterferon/Ribavirin for Black/African-American and Latino Patients with HCV infection. Ann Hepatol. 2016 Nov-Dec 2016;15(6):834-845

Additional resources
MetroHealth Logo